New hope for patients who have run out of options
NCT ID NCT07327411
Summary
This study is testing whether adding a drug called cetuximab β to a three-drug combination (called PRaG) can help control advanced solid tumors that have stopped responding to standard treatments. It is for adults whose tumors test positive for a specific marker called EGFR. The main goal is to see if this new combination can shrink tumors and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215163, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.